Parameter Set Anti-HIV Drugs - LC-MS/MS

Order No.: 92924/RUO
Parameters:
Amprenavir, Atazanavir, Darunavir, Efavirenz, Elvitegravir, Indinavir, Lopinavir, Maraviroc, Nelfinavir, Nelfinavir-M8, Raltegravir, Ritonavir, Saquinavir

Encompasses 17 analytes
6PLUS1® Multilevel Calibrator Set available
Part of the modular system MassTox® Series A

Amprenavir

Atazanavir

Darunavir

Delavirdine

Efavirenz

Elvitegravir

Etravirine

Indinavir

Lopinavir

Maraviroc

Nelfinavir

Nelfinavir-M8

Nevirapine

Raltegravir

Rilpivirine

Ritonavir

Saquinavir

Clinical relevance

This parameter set allows the quantitative determination of amprenavir, atazanavir, darunavir, delavirdine, efavirenz, elvitegravir, etravirine, indinavir, lopinavir, maraviroc, nelfinavir, nelfinavir-M8, nevirapine, raltegravir, rilpivirine, ritonavir and saquinavir in human serum or plasma samples via liquid chromatography mass spectrometry (LC-MS/MS).

 

MassTox® Series A

The MassTox® Series A is a modular system that enables the determination of all analytes without changing column or mobile phases, thereby minimising the workload in the laboratory.
It consists of 3 parts:
• MassTox® Basic Kit A
• Specific MassTox® Parameter Set
• Analytical column MassTox® TDM MasterColumn® A

More Information
Method of Analysis LC-MS/MS
Please note The freely available information on this website, in particular on the sample preparation, are not sufficient to work with our products. Please read instructions and warning notices on products and/or instruction manuals.
Specimen Serum/Plasma
Sample Preparation
  • Reconstitute the Internal Standard Mix.
  • Add 800 μl Internal Standard Mix to 12 ml Precipitation Reagent to form mixture A.
  • Pipette 50 μl research sample/calibrator/MassCheck® control into a 1.5 ml reaction vial.
  • Add 25 μl Extraction Buffer.
  • Mix and incubate 2 min at ambient temperature (do not centrifuge).
  • Add 250 μl of mixture A and mix 30 s minimum (vortex).
  • Centrifuge 5 min at 15000 x g.
  • Dilute the supernatant with Dilution Buffer prior to injection depending on the instrument sensitivity.
Run Time ≤ 3.5 min
Injection Volume 0.2 – 50 µl
Gradient

Group 1
0.00–0.20 min       0 % Mobile Phase 2
0.21–2.00 min     70 % Mobile Phase 2
2.01–2.90 min   100 % Mobile Phase 2
2.91–3.50 min       0 % Mobile Phase 2
Group 2
0.00–0.20 min       0 % Mobile Phase 2
0.21–0.60 min     50 % Mobile Phase 2
0.61–2.40 min     90 % Mobile Phase 2
2.41–3.00 min       0 % Mobile Phase 2
Group 3
0.00–0.20 min       0 % Mobile Phase 2
0.21–2.30 min     90 % Mobile Phase 2
2.31–3.10 min       0 % Mobile Phase 2

Ionisation ESI positive
MS/MS Mode MRM
Additional Info We recommend to set the scan time to a value that allows to achieve a minimum of 10 data points over the whole peak width.
Parameters Amprenavir, Atazanavir, Darunavir, Efavirenz, Elvitegravir, Indinavir, Lopinavir, Maraviroc, Nelfinavir, Nelfinavir-M8, Raltegravir, Ritonavir, Saquinavir
The following components are included in the kit:
The following products are not included in the kit but are required for the application of the method:

Amprenavir

Atazanavir

Darunavir

Delavirdine

Efavirenz

Elvitegravir

Etravirine

Indinavir

Lopinavir

Maraviroc

Nelfinavir

Nelfinavir-M8

Nevirapine

Raltegravir

Rilpivirine

Ritonavir

Saquinavir

Clinical relevance

This parameter set allows the quantitative determination of amprenavir, atazanavir, darunavir, delavirdine, efavirenz, elvitegravir, etravirine, indinavir, lopinavir, maraviroc, nelfinavir, nelfinavir-M8, nevirapine, raltegravir, rilpivirine, ritonavir and saquinavir in human serum or plasma samples via liquid chromatography mass spectrometry (LC-MS/MS).

 

MassTox® Series A

The MassTox® Series A is a modular system that enables the determination of all analytes without changing column or mobile phases, thereby minimising the workload in the laboratory.
It consists of 3 parts:
• MassTox® Basic Kit A
• Specific MassTox® Parameter Set
• Analytical column MassTox® TDM MasterColumn® A

More Information
Method of Analysis LC-MS/MS
Please note The freely available information on this website, in particular on the sample preparation, are not sufficient to work with our products. Please read instructions and warning notices on products and/or instruction manuals.
Specimen Serum/Plasma
Sample Preparation
  • Reconstitute the Internal Standard Mix.
  • Add 800 μl Internal Standard Mix to 12 ml Precipitation Reagent to form mixture A.
  • Pipette 50 μl research sample/calibrator/MassCheck® control into a 1.5 ml reaction vial.
  • Add 25 μl Extraction Buffer.
  • Mix and incubate 2 min at ambient temperature (do not centrifuge).
  • Add 250 μl of mixture A and mix 30 s minimum (vortex).
  • Centrifuge 5 min at 15000 x g.
  • Dilute the supernatant with Dilution Buffer prior to injection depending on the instrument sensitivity.
Run Time ≤ 3.5 min
Injection Volume 0.2 – 50 µl
Gradient

Group 1
0.00–0.20 min       0 % Mobile Phase 2
0.21–2.00 min     70 % Mobile Phase 2
2.01–2.90 min   100 % Mobile Phase 2
2.91–3.50 min       0 % Mobile Phase 2
Group 2
0.00–0.20 min       0 % Mobile Phase 2
0.21–0.60 min     50 % Mobile Phase 2
0.61–2.40 min     90 % Mobile Phase 2
2.41–3.00 min       0 % Mobile Phase 2
Group 3
0.00–0.20 min       0 % Mobile Phase 2
0.21–2.30 min     90 % Mobile Phase 2
2.31–3.10 min       0 % Mobile Phase 2

Ionisation ESI positive
MS/MS Mode MRM
Additional Info We recommend to set the scan time to a value that allows to achieve a minimum of 10 data points over the whole peak width.
Parameters Amprenavir, Atazanavir, Darunavir, Efavirenz, Elvitegravir, Indinavir, Lopinavir, Maraviroc, Nelfinavir, Nelfinavir-M8, Raltegravir, Ritonavir, Saquinavir
The following components are included in the kit:
The following products are not included in the kit but are required for the application of the method: